{"id":69296,"date":"2026-07-03T13:04:04","date_gmt":"2026-07-03T05:04:04","guid":{"rendered":"https:\/\/flcube.com\/?p=69296"},"modified":"2026-07-03T13:04:05","modified_gmt":"2026-07-03T05:04:05","slug":"novartis-secures-eu-approval-for-itvisma-first-gene-replacement-therapy-for-broad-sma-population-including-patients-two-years-and-older","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69296","title":{"rendered":"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Novartis AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>) announced that the <strong>European Commission (EC)<\/strong> has granted marketing authorization for <strong>Itvisma (onasemnogene abeparvovec)<\/strong>, a <strong>one-time gene replacement therapy<\/strong> for the treatment of <strong>children two years and older, adolescents, and adults<\/strong> living with <strong>5q spinal muscular atrophy (SMA)<\/strong> with bi-allelic mutations in the <strong>survival motor neuron 1 (SMN1) gene<\/strong>. This approval establishes Itvisma as the <strong>first and only gene replacement therapy<\/strong> approved in the European Union for this broad SMA population.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing Authorization<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Itvisma (onasemnogene abeparvovec) \u2013 gene replacement therapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>5q spinal muscular atrophy (SMA) in patients \u22652 years with bi-allelic SMN1 mutations<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>2 July 2026<\/td><\/tr><tr><td><strong>Therapeutic Distinction<\/strong><\/td><td>First and only gene replacement therapy approved for broad SMA population in EU<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-therapeutic-innovation-amp-mechanism\" class=\"wp-block-heading\">Therapeutic Innovation &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapy Type:<\/strong> <strong>One-time gene replacement therapy<\/strong> addressing the genetic root cause of SMA<\/li>\n\n\n\n<li><strong>Dosing Paradigm:<\/strong> <strong>Fixed dose<\/strong> that does not require adjustment for age or body weight<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong> Replaces the defective <strong>SMN1 gene<\/strong> to restore production of survival motor neuron (SMN) protein<\/li>\n\n\n\n<li><strong>Clinical Benefit:<\/strong> Improves motor function with sustained effects over 52 weeks<\/li>\n\n\n\n<li><strong>Treatment Differentiation:<\/strong> Distinct from ongoing dosing approaches of other available SMA therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-pivotal-trial-data\" class=\"wp-block-heading\">Clinical Evidence \u2013 Pivotal Trial Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Design<\/th><th>Key Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>STEER<\/strong><\/td><td>Registrational study<\/td><td>Primary basis for EC approval<\/td><\/tr><tr><td><strong>STRENGTH<\/strong><\/td><td>Phase IIIb supportive study<\/td><td>Confirmed efficacy and safety profile<\/td><\/tr><tr><td><strong>STRONG<\/strong><\/td><td>Phase I\/II supportive study<\/td><td>Additional clinical validation<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Hammersmith Functional Motor Scale (HFMSE)<\/td><td><strong>2.39-point statistically significant improvement<\/strong><\/td><\/tr><tr><td><strong>Durability<\/strong><\/td><td>52-week follow-up<\/td><td>Effects sustained throughout observation period<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-significance\" class=\"wp-block-heading\">Market Impact &amp; Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>SMA Patient Population<\/strong><\/td><td>Broad indication covering patients \u22652 years old with 5q SMA<\/td><\/tr><tr><td><strong>Current Treatment Landscape<\/strong><\/td><td>Existing therapies require ongoing administration (intrathecal injections or daily oral dosing)<\/td><\/tr><tr><td><strong>Competitive Advantage<\/strong><\/td><td>One-time treatment eliminates need for chronic therapy and associated burden<\/td><\/tr><tr><td><strong>Healthcare System Value<\/strong><\/td><td>Potential for reduced long-term healthcare utilization despite higher upfront cost<\/td><\/tr><tr><td><strong>Commercial Positioning<\/strong><\/td><td>Expands Novartis&#8217; leadership in rare disease gene therapy following Zolgensma&#8217;s success in younger patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-forward-outlook\" class=\"wp-block-heading\">Forward Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The EC approval significantly expands access to gene replacement therapy for the SMA community across Europe, addressing a critical unmet need for patients who previously had limited treatment options. By offering a one-time treatment that targets the fundamental genetic cause of SMA, Itvisma represents a paradigm shift in the management of this progressive neuromuscular disorder.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Novartis plans to work closely with European healthcare systems, patient advocacy groups, and regulatory bodies to ensure timely patient access. The company will leverage its established gene therapy infrastructure and manufacturing capabilities to support commercial launch across EU member states. This approval further strengthens Novartis&#8217; position as a leader in innovative gene therapies for rare neurological disorders.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for Itvisma. Actual results may differ due to risks including market access negotiations, reimbursement decisions, and competitive dynamics in the SMA therapeutic landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis AG (NYSE: NVS) announced that the European Commission (EC) has granted marketing authorization for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69298,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[66,140,865,15,24],"class_list":["post-69296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-gene-therapy","tag-novartis","tag-nyse-nvs","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis AG (NYSE: NVS) announced that the European Commission (EC) has granted marketing authorization for Itvisma (onasemnogene abeparvovec), a one-time gene replacement therapy for the treatment of children two years and older, adolescents, and adults living with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. This approval establishes Itvisma as the first and only gene replacement therapy approved in the European Union for this broad SMA population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69296\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older\" \/>\n<meta property=\"og:description\" content=\"Novartis AG (NYSE: NVS) announced that the European Commission (EC) has granted marketing authorization for Itvisma (onasemnogene abeparvovec), a one-time gene replacement therapy for the treatment of children two years and older, adolescents, and adults living with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. This approval establishes Itvisma as the first and only gene replacement therapy approved in the European Union for this broad SMA population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69296\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-03T05:04:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-03T05:04:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69296#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69296\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older\",\"datePublished\":\"2026-07-03T05:04:04+00:00\",\"dateModified\":\"2026-07-03T05:04:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69296\"},\"wordCount\":500,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69296#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0302.webp\",\"keywords\":[\"Gene therapy\",\"Novartis\",\"NYSE: NVS\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69296#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69296\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69296\",\"name\":\"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69296#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69296#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0302.webp\",\"datePublished\":\"2026-07-03T05:04:04+00:00\",\"dateModified\":\"2026-07-03T05:04:05+00:00\",\"description\":\"Novartis AG (NYSE: NVS) announced that the European Commission (EC) has granted marketing authorization for Itvisma (onasemnogene abeparvovec), a one-time gene replacement therapy for the treatment of children two years and older, adolescents, and adults living with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. This approval establishes Itvisma as the first and only gene replacement therapy approved in the European Union for this broad SMA population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69296#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69296\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69296#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0302.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69296#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis AG (NYSE: NVS) announced that the European Commission (EC) has granted marketing authorization for Itvisma (onasemnogene abeparvovec), a one-time gene replacement therapy for the treatment of children two years and older, adolescents, and adults living with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. This approval establishes Itvisma as the first and only gene replacement therapy approved in the European Union for this broad SMA population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69296","og_locale":"en_US","og_type":"article","og_title":"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older","og_description":"Novartis AG (NYSE: NVS) announced that the European Commission (EC) has granted marketing authorization for Itvisma (onasemnogene abeparvovec), a one-time gene replacement therapy for the treatment of children two years and older, adolescents, and adults living with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. This approval establishes Itvisma as the first and only gene replacement therapy approved in the European Union for this broad SMA population.","og_url":"https:\/\/flcube.com\/?p=69296","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-03T05:04:04+00:00","article_modified_time":"2026-07-03T05:04:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69296#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69296"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older","datePublished":"2026-07-03T05:04:04+00:00","dateModified":"2026-07-03T05:04:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69296"},"wordCount":500,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69296#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0302.webp","keywords":["Gene therapy","Novartis","NYSE: NVS","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69296#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69296","url":"https:\/\/flcube.com\/?p=69296","name":"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69296#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69296#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0302.webp","datePublished":"2026-07-03T05:04:04+00:00","dateModified":"2026-07-03T05:04:05+00:00","description":"Novartis AG (NYSE: NVS) announced that the European Commission (EC) has granted marketing authorization for Itvisma (onasemnogene abeparvovec), a one-time gene replacement therapy for the treatment of children two years and older, adolescents, and adults living with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. This approval establishes Itvisma as the first and only gene replacement therapy approved in the European Union for this broad SMA population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69296#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69296"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69296#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0302.webp","width":1080,"height":608,"caption":"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69296#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69296"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69296\/revisions"}],"predecessor-version":[{"id":69299,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69296\/revisions\/69299"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69298"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}